Free Trial

FY2024 EPS Estimates for kneat.com Raised by Stifel Canada

kneat.com logo with Medical background

kneat.com, inc. (TSE:KSI - Free Report) - Equities researchers at Stifel Canada lifted their FY2024 earnings per share (EPS) estimates for shares of kneat.com in a research note issued on Tuesday, November 12th. Stifel Canada analyst J. Keywood now forecasts that the company will post earnings per share of ($0.13) for the year, up from their previous estimate of ($0.15). The consensus estimate for kneat.com's current full-year earnings is ($0.12) per share. Stifel Canada also issued estimates for kneat.com's Q4 2024 earnings at ($0.03) EPS and FY2025 earnings at ($0.11) EPS.

Several other research analysts have also recently issued reports on KSI. Ventum Cap Mkts raised kneat.com to a "strong-buy" rating in a research note on Wednesday, August 7th. CIBC set a C$6.00 target price on kneat.com and gave the stock an "outperform" rating in a report on Tuesday, October 29th. Finally, Cibc World Mkts upgraded kneat.com to a "strong-buy" rating in a research note on Tuesday, October 29th.

Get Our Latest Research Report on KSI

kneat.com Price Performance

Shares of TSE KSI traded down C$0.04 during mid-day trading on Friday, hitting C$5.00. 57,336 shares of the company's stock traded hands, compared to its average volume of 58,824. The company has a market capitalization of C$430 million, a P/E ratio of -31.25, a PEG ratio of 597.67 and a beta of 1.08. The company's 50-day moving average is C$4.78 and its two-hundred day moving average is C$4.53. kneat.com has a 1 year low of C$2.80 and a 1 year high of C$5.17. The company has a debt-to-equity ratio of 95.14, a current ratio of 1.47 and a quick ratio of 1.50.

About kneat.com

(Get Free Report)

kneat.com, inc., together with its subsidiaries, designs, develops, and supplies software for data and document management within regulated environments in North America, Europe, and the Asia Pacific. The company offers the Kneat Gx platform, a configurable off-the-shelf application focused on validation lifecycle management and testing for biotechnology, pharmaceutical, and medical device manufacturing industries.

See Also

Earnings History and Estimates for kneat.com (TSE:KSI)

Should you invest $1,000 in kneat.com right now?

Before you consider kneat.com, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and kneat.com wasn't on the list.

While kneat.com currently has a "Strong Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

Investing Strategies To Help Grow Your Retirement Income Cover

Need to stretch out your 401K or Roth IRA plan? Use these time-tested investing strategies to grow the monthly retirement income that your stock portfolio generates.

Get This Free Report
Like this article? Share it with a colleague.

Featured Articles and Offers

Recent Videos

Why Whitestone REIT is Outperforming in 2024: 35% Growth & Monthly Dividends
Why SoundHound Stock Dip Could Mean Big Gains for 2025 Investors
Nintendo Stock: Buy Before the 2025 Switch Platform Hits!

Stock Lists

All Stock Lists

Investing Tools

Calendars and Tools

Search Headlines